FDA Probes Yaz, Others Over Blood Clot Risks
Two recently released studies cited by the FDA showed that the drugs increase the risk of venous thromboembolism by up to two to three times compared with other birth control pills. Other studies, though, have not found drospirenone to be riskier than its competition.
“The FDA is currently evaluating the conflicting...
To view the full article, register now.